查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2041792

流感診斷市場預測至2034年－按產品類型、檢測類型、最終用戶和地區分類的全球分析

Influenza Diagnostics Market Forecasts to 2034 - Global Analysis By Product, Test Type, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球流感診斷市場規模將達到 29.4 億美元，並在預測期內以 8.3% 的複合年成長率成長，到 2034 年將達到 55.7 億美元。

流感診斷是指識別和確認流感病毒感染的方法。快速檢測，例如抗原檢測，透過檢測呼吸道檢體中的病毒蛋白來快速得出結果。分子檢測，例如聚合酵素鏈鎖反應（PCR），透過檢測病毒的遺傳物質，具有較高的靈敏度和特異性。這些方法有助於早期診斷，並指導適當的治療和公共衛生干預。及時且準確的流感診斷能有效管理病患、控制疫情並促進疫苗研發。

根據世界衛生組織（世衛組織）的報告，2023年全球將出現約10億例季節性流感病例，其中300萬至500萬例為重症。此外，流感每年在全球造成29萬至65萬人死於呼吸系統疾病。

流感疫情蔓延

全球流感病例的不斷增加強烈表明，高效快速的診斷工具至關重要。市場對能夠快速準確檢測流感病毒的先進診斷技術的需求激增。這種需求的成長推動了創新診斷解決方案的研發，從而促進了市場擴張。隨著醫療系統將流感的早期發現和有效控制列為優先事項，以及應對流感疫情影響這一緊迫的全球健康挑戰，預計流感診斷市場將持續成長。

靈敏度和特異性的局限性

流感診斷在檢測流感病毒方面發揮著至關重要的作用，但區分亞型和病毒株的準確性仍存在問題。病毒的快速演化和抗原突變使得診斷方法的設計變得困難，導致假陰性結果和流感亞型辨識困難。假陽性和假陰性結果可能導致誤診，進而影響患者照護和公共衛生工作。平衡靈敏度和特異性仍然是流感診斷領域的複雜挑戰，阻礙了市場成長。

活性化研發活動

分子診斷和快速檢測等診斷技術的不斷進步，提高了流感檢測的準確性和效率。主要市場參與者加大研發投入，以及政府主導的各項舉措，推動了創新，進而催生了更可靠、更快速的診斷工具。研發活動的激增不僅帶來了技術突破，也為新的診斷解決方案鋪平了道路，最終促進了市場成長。此外，該領域研究的蓬勃發展也是市場擴張的關鍵驅動力。

與抗病毒藥物的競爭

隨著醫藥技術的不斷進步，抗病毒藥物作為流感的主要治療方法日益受到重視，這可能會降低對診斷工具的需求。有效抗病毒療法的普及可能會降低人們對快速且準確診斷方案的迫切需求，進而影響市場成長。醫療保健領域正朝著以治療為中心的模式轉變，凸顯了隨著流感管理動態的變化，診斷領域持續創新的必要性。

新冠疫情的影響

新冠疫情對流感診斷市場產生了重大影響。呼吸道感染疾病意識的提高、由於流感症狀與新冠肺炎症狀重疊而導致的診斷檢測需求激增，以及醫療基礎設施的擴建，都對市場產生了積極影響。此外，對先進診斷技術和病毒學研究的日益關注也推動了流感診斷領域的創新。然而，疫情期間供應鏈和醫療服務的中斷也帶來了挑戰。整體而言，受疫情影響，市場正經歷動態變化，機會與挑戰並存。

在預測期內，血清學檢測領域預計將成為最大的細分市場。

血清學檢測領域預計將成為高盈利成長點。血清學檢測透過檢測患者血清中的抗體，在流感診斷中發揮至關重要的作用，有助於識別和監測流感感染。此方法有助於區分當前感染和既往感染，並能全面了解個體的免疫反應。總而言之，血清學檢測的多功能性提高了診斷準確性，有助於制定預防策略，並加強對流感感染的整體管理。

預計在預測期內，臨床檢查室領域將呈現最高的複合年成長率。

預計在預測期內，臨床檢查室領域將呈現最高的複合年成長率。在臨床檢查室中，流感診斷在患者照護和公共衛生方面發揮著至關重要的作用。快速且準確地識別流感病毒有助於確定合適的治療策略，並降低疾病的嚴重程度和持續時間。包括PCR檢測和快速抗原檢測在內的診斷測試能夠實現早期發現，並幫助醫護人員實施感染控制措施，以防止感染進一步傳播。這些測試能夠改善患者預後，支持公共衛生工作，並指南疫苗接種策略，充分體現了臨床檢查室在有效管理和控制流感方面發揮的關鍵作用。

市佔率最大的地區：

由於公眾意識的提高、醫療保健支出的成長以及流感病例的激增，預計亞太地區將在預測期內佔據最大的市場佔有率。 PCR 和快速流感檢測等先進診斷技術在該地區正日益普及。此外，政府措施和對就地檢驗需求的不斷成長也推動了市場擴張。羅氏診斷、雅培和賽默飛世爾科技等領導企業正致力於策略聯盟和產品創新，以鞏固其市場地位。在積極的公共衛生措施和診斷技術的不斷發展的推動下，亞太地區的流感診斷市場預計將持續成長。

複合年成長率最高的地區：

由於流感疫情的廣泛爆發以及對精準快速診斷解決方案的持續需求，預計北美地區在預測期內將呈現最高的複合年成長率。該地區對快速、高靈敏度診斷工具的需求強勁，推動了技術進步。市場上的主要參與者，例如 Luminex 公司、DiaSorin 公司和貝克頓·迪金森公司 (BD)，正致力於開發 PCR 和免疫檢測等創新技術，以實現高效的流感檢測。此外，政府措施、公眾意識的提高以及對就地檢驗的需求等因素也對市場產生了影響。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域細分
    • 應客戶要求，我們提供主要國家的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對領先公司進行基準分析。

目錄

第1章執行摘要

第2章：引言

  • 概括
  • 相關利益者
  • 調查範圍
  • 調查方法
  • 研究材料

第3章 市場趨勢分析

  • 促進因素
  • 抑制因子
  • 機會
  • 威脅
  • 產品分析
  • 最終用戶分析
  • 新興市場
  • 新冠疫情的感染疾病

第4章：波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的競爭

第5章 全球流感診斷市場：依產品分類

  • 裝置
  • 試劑盒和試劑
  • 其他產品

第6章：全球流感診斷市場：依檢測類型分類

  • 常規診斷測試
    • 病毒培養
    • 直接螢光試驗（DFAT）
    • 快速流感診斷測試（RIDT）
  • 分子診斷檢測
    • 簡化擴增法（SAMBA）
    • 基於核酸序列的擴增檢測（NASBAT）
    • 恒溫環型核酸擴增（LAMP）
    • 逆轉錄聚合酵素鏈鎖反應（RT-PCR）
  • 血清學檢測
    • 血凝抑制（HI）法
    • 微量中和試驗
  • 其他測試類型

第7章 全球流感診斷市場：依最終用戶分類

  • 即時檢測
  • 醫院
  • 臨床實驗室
  • 學術和研究機構
  • 居家醫療
  • 其他最終用戶

第8章 全球流感診斷市場：依地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太國家
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • UAE
    • 卡達
    • 南非
    • 其他中東和非洲國家

第9章 主要發展

  • 合約、夥伴關係、合作關係、合資企業
  • 收購與併購
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第10章：公司簡介

  • Altona Diagnostics GmbH
  • ELITech Group
  • GenMark Diagnostics
  • F. Hoffmann-La Roche Ltd
  • Abbott Laboratories
  • Becton, Dickinson, and Company
  • Coris BioConcept
  • DiaSorin SpA
  • Meridian Bioscience Inc.
  • Quidel Corporation
  • Sekisui Diagnostics
  • Thermo Fischer Scientific Inc.
  • Hologic Inc.
  • Mast Group
  • Siemens Healthineers AG
  • BioMerieux SA
  • Luminex Corporation
Product Code: SMRC24856

According to Stratistics MRC, the Global Influenza Diagnostics Market is accounted for $2.94 billion in 2026 and is expected to reach $5.57 billion by 2034 growing at a CAGR of 8.3% during the forecast period. Influenza diagnostics involve methods to identify and confirm influenza virus infections. Rapid tests, such as antigen detection assays, provide quick results by detecting viral proteins in respiratory samples. Molecular tests, like polymerase chain reaction (PCR), offer high sensitivity and specificity by detecting viral genetic material. These methods aid in early diagnosis, guiding appropriate treatment and public health interventions. Timely and accurate influenza diagnostics enables effective patient management, outbreak control and vaccine development.

According to the World Health Organization report, in 2023, there were around a billion cases of seasonal influenza annually, including 3-5 million cases of severe illness. Moreover, influenza causes 290,000 to 650,000 respiratory deaths annually around the globe.

Market Dynamics:

Driver:

Rising prevalence of influenza

The increasing incidence of influenza cases worldwide underscores the critical need for efficient and rapid diagnostic tools. The market is witnessing a surge in demand for advanced diagnostic technologies capable of swift and accurate detection of influenza viruses. This heightened demand is steering research and development efforts towards innovative diagnostic solutions, fostering market expansion. As healthcare systems prioritize early detection and effective management of influenza, the influenza diagnostics market is poised to witness sustained growth, driven by the urgent global health imperative to mitigate the impact of influenza outbreaks.

Restraint:

Limited sensitivity & specificity

While influenza diagnostics play a crucial role in detecting influenza viruses, their accuracy in differentiating between subtypes and strains remains a concern. Rapid evolution and antigenic variability challenge the design of diagnostics, leading to false negatives or difficulty in distinguishing between influenza subtypes. False positives and negatives can lead to misdiagnoses, impacting patient care and public health efforts. Balancing the trade-off between sensitivity and specificity remains a complex task in influenza diagnostics, which hinder the market growth.

Opportunity:

Growing research & development activities

Ongoing advancements in diagnostic technologies, such as molecular and rapid testing methods, are enhancing the accuracy and efficiency of influenza detection. Increasing investments in R&D by key market players and government initiatives are driving innovation, leading to the development of more reliable and rapid diagnostic tools. This surge in R&D activities not only fosters technological breakthroughs but also opens avenues for novel diagnostic solutions, ultimately propelling the growth of the market. Also, the dynamic landscape of research in this field positions it as a crucial driver for market expansion.

Threat:

Competition from antiviral medications

As pharmaceutical advancements continue, antiviral drugs gain prominence as a primary intervention for influenza, potentially diminishing the demand for diagnostic tools. The availability of effective antiviral treatments may reduce the urgency for rapid and accurate diagnostic solutions, impacting the market's growth. The healthcare landscape's shift towards treatment-oriented approaches underscores the need for constant innovation in diagnostics to maintain relevance and competitiveness amid the evolving dynamics of influenza management.

Covid-19 Impact

The covid-19 pandemic has significantly influenced the influenza diagnostics market. Increased awareness of respiratory infections, heightened demand for diagnostic testing due to overlapping symptoms with covid, and a surge in healthcare infrastructure have positively impacted the market. Additionally, the focus on advanced diagnostic technologies and research in virology has driven innovation in influenza diagnostics. However, disruptions in the supply chain and healthcare services during the pandemic have presented challenges. Overall, the market has experienced a dynamic shift with both opportunities and obstacles arising from the epidemic impact.

The serological testing segment is expected to be the largest during the forecast period

The serological testing segment is estimated to have a lucrative growth. Serological testing plays a crucial role in Influenza Diagnostics by detecting antibodies in a patient's blood serum, aiding in the identification and monitoring of influenza infections. This method helps differentiate between current and past infections, allowing for a comprehensive understanding of an individual's immune response. Overall, the versatility of serological testing enhances diagnostic accuracy, informs preventative strategies, and strengthens the overall management of influenza infections.

The clinical laboratories segment is expected to have the highest CAGR during the forecast period

The clinical laboratories segment is anticipated to witness the highest CAGR growth during the forecast period. In clinical laboratories, influenza diagnostics play a pivotal role in patient care and public health. Rapid and accurate identification of influenza viruses aids in timely treatment decisions, reducing the severity and duration of illness. Diagnostic tests, including PCR and rapid antigen assays, enable early detection, helping healthcare professionals implement infection control measures to prevent further transmission. These tests enhance patient outcomes, support public health initiatives, and inform vaccination strategies, demonstrating their indispensable role in clinical laboratories for effective influenza management and control.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period owing to the increased awareness, rising healthcare expenditure, and a surge in influenza cases. Advanced diagnostic technologies, such as PCR and rapid influenza detection tests, are gaining prominence in the region. Additionally, government initiatives coupled with the growing demand for point-of-care testing, are driving market expansion. Key players such as Roche Diagnostics, Abbott Laboratories and Thermo Fisher Scientific are focusing on strategic collaborations and product innovations to strengthen their market presence. The Asia Pacific Influenza Diagnostics Market is poised for continued growth, driven by a proactive approach to public health and the continual evolution of diagnostic technologies.

Region with highest CAGR:

North America is projected to have the highest CAGR over the forecast period, owing to the increasing prevalence of influenza and the constant need for accurate and timely diagnostic solutions. The region witnesses a robust demand for rapid and sensitive diagnostic tools, driving technological advancements. Key players in the market like Luminex Corporation, DiaSorin and Becton, Dickinson and Company (BD) focus on innovative techniques like PCR and immunoassays for efficient influenza detection. The market is influenced by factors such as government initiatives, rising awareness, and the need for point-of-care testing.

Key players in the market

Some of the key players profiled in the Influenza Diagnostics Market include Altona Diagnostics GmbH, ELITech Group, GenMark Diagnostics, F. Hoffmann-La Roche Ltd, Abbott Laboratories, Becton, Dickinson, and Company, Coris BioConcept, DiaSorin SpA, Meridian Bioscience Inc., Quidel Corporation, Sekisui Diagnostics, Thermo Fischer Scientific Inc., Hologic Inc., Mast Group, Siemens Healthineers AG, BioMerieux SA and Luminex Corporation.

Key Developments:

In September 2022, Siemens Healthineers released its new CE-marked FTD SARS-CoV-2/FluA/FluB/HRSV Assay, a PCR test, and the CLINITEST Rapid COVID-19 + Influenza Antigen Test. Validated on the company's VERSANT kPCR Molecular System, the kit combines Siemens Healthineers FTD SARS-CoV-23 and FTD Flu/HRSV Assays.

In February 2022, Roche announced the expansion of the COVID-19 PCR portfolio to the cobas(R) 5800 System, a recently launched molecular laboratory instrument, in countries accepting the CE mark. These include cobas SARS-CoV-2 Qualitative and cobas SARS-CoV-2 & Influenza A/B tests. These launches expand the Roche Diagnostics molecular portfolio offering by providing standardized performance and efficiencies across low, medium and high volume molecular laboratory testing needs.

Products Covered:

  • Instruments
  • Kits & Reagents
  • Other Products

Test Types Covered:

  • Traditional Diagnostic Test
  • Molecular Diagnostic Assay
  • Serological Testing
  • Other Test Types

End Users Covered:

  • Point-of-Care Testing
  • Hospitals
  • Clinical Laboratories
  • Academic/Research Institutes
  • Homecare Settings
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Influenza Diagnostics Market, By Product

  • 5.1 Introduction
  • 5.2 Instruments
  • 5.3 Kits & Reagents
  • 5.4 Other Products

6 Global Influenza Diagnostics Market, By Test Type

  • 6.1 Introduction
  • 6.2 Traditional Diagnostic Test
    • 6.2.1 Viral Culture
    • 6.2.2 Direct Fluorescent Antibody Test (DFAT)
    • 6.2.3 Rapid Influenza Diagnostic Test (RIDT)
  • 6.3 Molecular Diagnostic Assay
    • 6.3.1 Simple Amplification-based Assay (SAMBA)
    • 6.3.2 Nucleic Acid Sequence-based Amplification Test (NASBAT)
    • 6.3.3 Loop-mediated Isothermal Amplification-based Assay (LAMP)
    • 6.3.4 Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)
  • 6.4 Serological Testing
    • 6.4.1 Hemagglutination Inhibition (HI) Assays
    • 6.4.2 Microneutralization Assays
  • 6.5 Other Test Types

7 Global Influenza Diagnostics Market, By End User

  • 7.1 Introduction
  • 7.2 Point-of-Care Testing
  • 7.3 Hospitals
  • 7.4 Clinical Laboratories
  • 7.5 Academic/Research Institutes
  • 7.6 Homecare Settings
  • 7.7 Other End Users

8 Global Influenza Diagnostics Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Altona Diagnostics GmbH
  • 10.2 ELITech Group
  • 10.3 GenMark Diagnostics
  • 10.4 F. Hoffmann-La Roche Ltd
  • 10.5 Abbott Laboratories
  • 10.6 Becton, Dickinson, and Company
  • 10.7 Coris BioConcept
  • 10.8 DiaSorin SpA
  • 10.9 Meridian Bioscience Inc.
  • 10.10 Quidel Corporation
  • 10.11 Sekisui Diagnostics
  • 10.12 Thermo Fischer Scientific Inc.
  • 10.13 Hologic Inc.
  • 10.14 Mast Group
  • 10.15 Siemens Healthineers AG
  • 10.16 BioMerieux SA
  • 10.17 Luminex Corporation

List of Tables

  • Table 1 Global Influenza Diagnostics Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Influenza Diagnostics Market Outlook, By Product (2023-2034) ($MN)
  • Table 3 Global Influenza Diagnostics Market Outlook, By Instruments (2023-2034) ($MN)
  • Table 4 Global Influenza Diagnostics Market Outlook, By Kits & Reagents (2023-2034) ($MN)
  • Table 5 Global Influenza Diagnostics Market Outlook, By Other Products (2023-2034) ($MN)
  • Table 6 Global Influenza Diagnostics Market Outlook, By Test Type (2023-2034) ($MN)
  • Table 7 Global Influenza Diagnostics Market Outlook, By Traditional Diagnostic Test (2023-2034) ($MN)
  • Table 8 Global Influenza Diagnostics Market Outlook, By Viral Culture (2023-2034) ($MN)
  • Table 9 Global Influenza Diagnostics Market Outlook, By Direct Fluorescent Antibody Test (DFAT) (2023-2034) ($MN)
  • Table 10 Global Influenza Diagnostics Market Outlook, By Rapid Influenza Diagnostic Test (RIDT) (2023-2034) ($MN)
  • Table 11 Global Influenza Diagnostics Market Outlook, By Molecular Diagnostic Assay (2023-2034) ($MN)
  • Table 12 Global Influenza Diagnostics Market Outlook, By Simple Amplification-based Assay (SAMBA) (2023-2034) ($MN)
  • Table 13 Global Influenza Diagnostics Market Outlook, By Nucleic Acid Sequence-based Amplification Test (NASBAT) (2023-2034) ($MN)
  • Table 14 Global Influenza Diagnostics Market Outlook, By Loop-mediated Isothermal Amplification-based Assay (LAMP) (2023-2034) ($MN)
  • Table 15 Global Influenza Diagnostics Market Outlook, By Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) (2023-2034) ($MN)
  • Table 16 Global Influenza Diagnostics Market Outlook, By Serological Testing (2023-2034) ($MN)
  • Table 17 Global Influenza Diagnostics Market Outlook, By Hemagglutination Inhibition (HI) Assays (2023-2034) ($MN)
  • Table 18 Global Influenza Diagnostics Market Outlook, By Microneutralization Assays (2023-2034) ($MN)
  • Table 19 Global Influenza Diagnostics Market Outlook, By Other Test Types (2023-2034) ($MN)
  • Table 20 Global Influenza Diagnostics Market Outlook, By End User (2023-2034) ($MN)
  • Table 21 Global Influenza Diagnostics Market Outlook, By Point-of-Care Testing (2023-2034) ($MN)
  • Table 22 Global Influenza Diagnostics Market Outlook, By Hospitals (2023-2034) ($MN)
  • Table 23 Global Influenza Diagnostics Market Outlook, By Clinical Laboratories (2023-2034) ($MN)
  • Table 24 Global Influenza Diagnostics Market Outlook, By Academic/Research Institutes (2023-2034) ($MN)
  • Table 25 Global Influenza Diagnostics Market Outlook, By Homecare Settings (2023-2034) ($MN)
  • Table 26 Global Influenza Diagnostics Market Outlook, By Other End Users (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.